Survivin: A promising tumor biomarker

Cancer Letters

Volumn 249, Issue 1, 2007, Pages 49-60

  Duffy, Michael J ^a,b   O'Donovan, Norma ^c   Brennan, Donal J ^b   Gallagher, William M ^b   Ryan, Bríd M ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Angiogenesis; Apoptosis; Proliferation; Survivin; Tumor marker

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; IMATINIB; PACLITAXEL; SURVIVIN; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; MICROMETASTASIS; MITOSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN STRUCTURE; SHORT SURVEY; TISSUE DIFFERENTIATION;

EID: 33947426098     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.020     Document Type: Review

References (106)

1. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3 (2003) 46-54
2. Li F. Survivin study: what is the next wave?. J. Cell Physiol. 197 (2003) 8-29
3. Velculescu V.E., Madden S.L., Zhang L., Lash A.E., Yu J., Rago C., Lal A., Wang C.J., Beaudry G.A., Ciriello K.M., Cook B.P., Dufault M.R., Ferguson A.T., Gao Y., He T.C., Hermeking H., Hiraldo S.K., Hwang P.M., Lopez M.A., Luderer H.F., Mathews B., Petroziello J.M., Polyak K., Zawel L., Zhang W., Zhang X., Zhou W., Haluska J.J., Sukumar S., Landes G.M., Riggins G.J., Vogelstein B., and Kinzler K.W. Analysis of human transcriptomes. Nat. Genet. 23 (1999) 387-388
4. Deveraux Q.L., and Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
5. Cheung H., LaCasse E.C., and Korneluk R.G. X-linked inhibitor of apoptosis antagonism: strategies in cancer treatment. Clin. Cancer Res. 12 (2006) 3238-3242
6. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., and Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7 (2000) 602-608
7. Mahotka C., Wenzel M., Springer E., Gabbert H.E., and Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59 (1999) 6097-6102
8. Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., and Inuzuka M. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem. Biophys. Res. Commun. 314 (2004) 902-907
9. Caldas H., Honsey L.E., and Altura R.A. Survivin 2α: a novel survivin splice variant expressed in human malignancies. Mol. Cancer 4 (2005) 11
10. Fortugno P., Wall N.R., Giodini A., O'Connor D.S., Plescia J., Padgett K.M., Tognin S., Marchisio P.C., and Altieri D.C. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 115 (2002) 575-585
11. Dohi T., Beltrami E., Wall N.R., Plescia J., and Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 114 (2004) 1117-1127
12. Mahotka C., Liebmann J., Wenzel M., Suschek C.V., Schmitt M., Gabbert H.E., and Gerharz C.D. Differential subcellular localization of divergent splice variants. Cell Death Diff. 9 (2002) 1334-1342
13. Caldas H., Jiang Y., Holloway M.P., Fangusaro J., Mahotka C., Conway E.M., and Altura R.A. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 24 (2005) 1994-2007
14. Rodriguez J.A., Span S.W., Ferreira C.G., Kruyt F.A., and Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the anti-apoptotic protein survivin. Exp. Cell Res. 275 (2002) 44-53
15. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., and Altieri D.C. Control of apoptosis and apoptotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
16. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., Villa A., Marchisio P.C., and Altieri D.C. Pleiotrophic cell-divisions defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1 (1999) 461-466
17. Grossman D., Kim P.J., Blanc-Brude O., Brash D.E., Tognin S., Marchisio P.C., and Altieri D.C. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108 (2001) 991-999
18. Mesri M., Wall N.R., Li J., Kim R.W., and Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108 (2001) 981-990
19. Olie R.A., Simoes-Wust A.P., Baumann B., Leech S.H., Fabbro D., Stahel R.A., and Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60 (2000) 2085-2809
20. Pennati M., Colella G., Folini L., Citti L., Daidone M.G., and Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cis-platin-induced apoptosis. J. Clin. Invest. 109 (2002) 285-286
21. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., Luo W., Devriese A., Lupu F., Bono F., Leducq N., Dol F., Schaeffer P., Collen D., and Herbert J.M. Deficiency of survivin in transgenic mice exacerbates fas-induced apoptosis via mitchondrial pathways. Gastroenterology 123 (2002) 619-631
22. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., and Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res. 58 (1998) 5315-5320
23. Shin B.C., Sung B.J., Kim H., Kim H.J., Ha N.C., Hwang J.I., Chung C.W., Jung Y.K., and Oh B.H. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
24. Banks D.P., Plescia J., and Altieri D.C. Survivin does not inhibit caspase-3 activity. Blood 96 (2000) 4002
25. Chantalat L., Skoufias D.A., Kleman L.P., Jung B., Dideberg O., and Margolis R.L. Crystal structure of human survivin reveals a bow tie-shaped dimer with 2 unusual alpha-helical extensions. Mol. Cell 6 (2000) 183-189
26. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
27. Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., and Reed J.C. HBXIP functions as a cofactor of surviving in apoptosis suppression. EMBO J. 22 (2003) 2729-2740
28. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., and Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 279 (2004) 34087-34090
29. Du C., Fang M., Li Y., Li L., and Wang X. Smac a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
30. Song Z., Yao X., and Wu M. Direct interaction between survivin and SMAC is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 278 (2003) 23130-23140
31. Zhu N., Gu L., Findley H.W., Li F., and Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23 (2004) 7545-7551
32. Yang D., Welm A., and Bishop J.M. Cell survival in the absence of survivin. Proc. Natl. Acad. Sci. USA 101 (2004) 15100-15105
33. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4 (2004) 592-603
34. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., and Choo K.H. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10 (2000) 1319-1328
35. Okada H., Bakal C., Shahinian A., Elia A., Wakeham A., Suh W.K., Duncan G.S., Ciofani M., Rottapel R., Zuniga-Pflucker J.C., and Mak T.W. Survivin loss in thymocytes triggers p53 mediated growth arrest and p53-independent cell death. J. Exp. Med. 199 (2004) 399-410
36. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., Symons M., and Altieri D.C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 62 (2002) 2462-2467
37. Williams N.S., Gaynor R.B., Scoggin S., Verma U., Gokaslan T., Simmang C., Fleming J., Tavana D., Frenkel E., and Becerra C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin. Cancer Res. 9 (2003) 931-946
38. Ansell S.M., Arendt B.K., Grote D.M., Jelinek D.F., Novak A.J., Wellik L.E., Remstein E.D., Bennett C.F., and Fielding A. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 18 (2004) 616-623
39. Uren A.G., Beilharz T., O'Connell M.J., Bugg S.J., van Driel R., Vaux C.L., and Lithgow T. Role for yeast inhibitor of apoptosis (IAP)-like proteins in cell division. Proc. Natl. Acad. Sci. USA 96 (1999) 10170-10175
40. Fraser A.G., James C., Evan G.I., and Hengartner M.O. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue (BIR-1) plays a conserved role in cytokinesis. Curr.Biol. 9 (1999) 292-301
41. Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., and Reed J.C. CIAP1 localizes to the nuclear compartment and modulates the cell cycle. Cancer Res. 65 (2005) 210-218
42. Vader G., Kauw J.J., Medema R.H., and Lens S.M. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep. 7 (2006) 85-92
43. O'Connor D.S., Schechner J.S., Adida C., Mesri M., Rothermel A.L., Li F., Nath A.K., Pober J.S., and Altieri D.C. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156 (2000) 393-398
44. Tran J., Rak J., Sheehan C., Saibil S.D., LaCasse E., Korneluk R.G., and Kerbel R.S. Marked induction of IAP family antiapoptotic protein survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264 (1999) 781-788
45. Tran J., Master Z., Yu J.L., Saibil S.D., LaCasse E., Korneluk R.G., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 99 (2002) 4349-4354
46. Conway E.M., Zwerts F., Van Eygen V., DeVriese A., Nagai N., Luo W., and Collen D. Survivin-dependent angiogenesis in ischemic brain, molecular mechanisms of hypoxia-induced up-regulation. Am. J. Pathol. 163 (2003) 935-946
47. Kawasaki H., Toyoda M., Shinohara H., Okuda J., Watanabe I., Yamamoto T., Tanaka K., Tenjo T., and Tanigawa N. Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal carcinogenesis. Cancer 91 (2001) 2026-2032
48. Tu S.P., Jiang X.H., Lin M.C., Cui J.T., Yang Y., Lum C.T., Zou B., Zhu Y.B., Jiang S.H., Wong W.M., Chan A.O., Yuen M.F., Lam S.K., Kung H.F., and Wong B.C. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 63 (2003) 7724-7732
49. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., and Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Cancer Res. 9 (2003) 2683-2692
50. Allen S.M., Florell S.R., Hanks A.N., Alexander A., Diedrich M.J., Altieri D.C., and Grossman D. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res. 63 (2003) 567-572
51. Satoh K., Kaneko K., Hirota M., Masamune A., Satoh A., and Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92 (2001) 271-278
52. Singh M., Bleile M.J., Shroyer L., Heinz D., Jarboe E.A., and Shroyer K.R. Analysis of survivin expression in a spectrum of benign to malignant lesions of the breast. Appl. Immunohistochem. Mol. Morphol. 12 (2004) 296-304
53. Krajewska M., Krajewski S., Banares S., Huang X., Turner B., Bubendorf L., Kallioniemi O.P., Shabaik A., Vitiello A., Peehl D., Gao G.J., and Reed J.C. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Cancer Res. 9 (2003) 4914-4925
54. Shariat S.F., Lotan Y., Saboorian H., Khoddami S.M., Roehrborn C.G., Slawin K.M., and Ashfaq R. Survivin expression is associated with features of biologically aggressive carcinoma. Cancer 100 (2004) 751-757
55. Kim H.S., Shiraki K., and Park S.H. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res. 22 (2002) 805-808
56. Frost M., Jarboe E.A., Orlicky D., Gianani R., Thompson L.C., Enomoto T., and Shroyer K.R. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia and invasive squamous cell carcinoma. Am. J. Clin. Path. 117 (2002) 738-744
57. Moon W.S., and Tarnawski A.S. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?. Human Pathol. 34 (2003) 1119-1126
58. Ding Y., Prieto V.G., Zhang P.S., Rosenthal S., Smith K.J., Skelton H.G., and Diwan A.H. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 106 (2006) 1123-1129
59. Duffy M.J. Clinical uses of Tumor markers: a critical review. Crit. Rev. Clin. Lab. Sci. 38 (2001) 225-262
60. Schultz I.J., Witjes J.A., Swinkels D.W., and de Kok J.B. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin. Chim. Acta 368 (2006) 20-32
61. Smith S.D., Wheeler M.A., Plescia J., Colberg J.W., Weiss R.M., and Altieri D.C. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
62. Shariat S.F., Casella R., Khoddami S.M., Hernandez G., Sulser T., Gasser T.C., and Lerner S.P. Urine detection of surviving is a sensitive marker for the non-invasive diagnosis of bladder cancer. J. Urol. 171 (2004) 626-630
63. Weikert S., Christoph F., Schrader M., Krause H., Miller K., and Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int. J. Cancer 116 (2005) 100-104
64. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R., and Shroyer K.R. Expression of survivin in normal, hyperplastic and neoplastic colonic tissue. Human Pathol. 42 (2001) 119-125
65. Fukuda S., Foster R.G., Porter S.B., and Pelus L.M. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100 (2002) 2463-2471
66. Pennartz S., Belvindrah R., Tomiuk S., Zimmer C., Hofmann K., Conradt M., Bosio A., and Cremer H. Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol. Cell Neurosci. 25 (2004) 692-706
67. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
68. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., Borgen P.I., Clark G., Edge S.B., Hayes D.F., Hughes L.L., Hutter R.V., Morrow M., Page D.L., Recht A., Theriault R.L., Thor A., Weaver D.L., Wieand H.S., and Greene F.L. Revision of the American Joint Committee on cancer staging system for breast cancer. J. Clin. Oncol. 20 (2002) 3628-3636
69. Pantel K., Cote R.J., and Fodstad O. Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91 (1999) 1113-1124
70. Gradilone A., Gazzaniga P., Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi N., Frati L., and Agliano A.M. Survivin, bcl-2, bax and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 21 (2002) 306-312
71. Duffy M.J. CEA as a marker for colorectal cancer: is it clinically useful. Clin. Chem. 47 (2001) 624-630
72. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., and Altieri D.C. Anti-apoptotic gene, survivin, and prognosis of neuroblastoma. Lancet 351 (1998) 882-883
73. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., Barnadas A., and Abad A. A novel anti-apoptosis gene: re-expression of survivin mRNA as a prognostic marker in non-small-cell lung cancers. J. Clin. Oncol. 17 (1999) 2100-2104
74. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., Gisselbrecht C., Salles G., Altieri D.C., and Molina T.J. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96 (2000) 1921-1925
75. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptotic gene survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
76. Rodel F., Hoffmann J., Grabenbauer G.G., Papadopoulos T., Weiss C., Gunther K., Schick C., Sauer R., and Rodel C. High survivin expression is associated with reduced apoptosis in rectal cancer may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol. 178 (2002) 426-435
77. Rodel F., Hoffmann J., Distel L., Herrmann M., Noisternig T., Papadopoulos T., Sauer R., and Rodel C. Survivin as a radioresistance factor and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 65 (2005) 4881-4887
78. Kappler M., Kohler T., Kampf C., Diestelkotter P., Wurl P., Schmitz M., Bartel F., Lautenschlager C., Rieber E.P., Schmidt H., Bache M., Taubert H., and Meye A. Increased survivin transcript levels: an independent predictor of survival in soft tissue sarcoma patients. Int. J. Cancer 95 (2001) 360-363
79. Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., and Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int. J. Oncol. 21 (2002) 315-320
80. Takai N., Azaki T.M., Nishida M., Nasu K., and Miyakawa I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int. J. Mol. Med. 10 (2002) 211-216
81. Takai N., Miyazaki T., Nishida M., Nasu K., and Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior, and survival rate in endometrial carcinoma. Cancer Lett. 184 (2002) 105-116
82. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., Mitsui A., Nishiwaki T., Moriyama S., Kudo J., and Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95 (2001) 92-95
83. Grabowski P., Kuhnel T., Muhr-Wilkenshoff F., Heine B., Stein H., Hopfner C.T., Germer C.T., and Scherubl H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 88 (2002) 115-119
84. Chakravarti A., Noll E., Black P.M., Finkelstein D.F., Finkelstein D.M., Dyson N.J., and Loeffler J.S. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20 (2002) 1063-1068
85. Span P.N., Sweep F.C., Wiegerinck E.T., Tjan-Heijnen V.C., Manders P., Beex L.V., and de Kok B. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin. Chem. 50 (2004) 1983-1986
86. Ryan B.M., Konecny G., Kahlert S., Wang H., Untch M., Meng G., Pegram M.D., Podratz K.C., Corwn J., Slamon D.J., and Duffy M.J. Survivin expression in breast cancer predicts clinical outcome and is associated with HER-2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol. 52 (2006) 345-351
87. Swana H.S., Grossman D., Anthony J.N., Weiss R.M., and Altieri D.C. Tumor content of the anti-apoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341 (1999) 452-453
88. Li F., Yang J., Rammath N., Javle M.M., and Tan D. Nuclear or cytoplasmic expression of survivin: what is significant?. Int. J. Cancer 114 (2005) 509-512
89. Mahotka C., Krieg T., Krieg A., Wenzel M., Suschek C.V., Heydthausen M., Gabbert H.E., and Gerharz C.D. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int. J. Cancer 100 (2002) 30-36
90. Krieg A., Mahotka C., Krieg T., Grabsch H., Muller W., Takeno S., Suschek C.V., Heydthausen M., Gabbert H.E., and Gerharz C.D. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumor progression. Br. J. Cancer 86 (2002) 737-743
91. Ling X., Yang J., Tan D., Ramnath N., Younis T., Bundy B.N., Slocum H.K., Yang L., Zhou M., and Li F. Differential expression of survivin-2B and survivin-Δex3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 49 (2005) 353-361
92. Taubert H., Kappler M., Bache M., Bartel F., Kohler T., Lautenschlager C., Blumke K., Wurl P., Schmidt H., Meye A., and Hauptmann S. Elevated expression of survivin splice variants predicts a poor outcome for soft-tissue sarcoma patients. Oncogene 24 (2005) 5258-5261
93. Span P.N., Tjan-Heijnen V.C., Heuvel J.J., de Kok J.B., Foekens J., and Sweep F.C. Do the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer. Clin. Chem. 52 (2006) 1070-1079
94. Johnstone R.W., Ruefli A.A., and Lowe S. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
95. Grossman D., Kim P.J., Schechner J.S., and Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 98 (2001) 635-640
96. Zaffaroni N., Pennat M., Colella G., Perego P., Supino R., Gatti L., Pilotti S., and Daidone F.M.G. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 59 (2002) 1406-1412
97. Ling X., Bernacki R.J., Brattain M.G., and Li F. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent of taxol-mediated G2/M arrest. J. Biol. Chem. 279 (2004) 15196-15203
98. Pennati M., Binda M., Colella G., Zoppe' M., Folini M., Vignati S., Valentini A., Citti L., De Cesare M., Pratesi G., Giacca M., Daidone M.G., and Zaffaroni N. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23 (2004) 386-394
99. Zhang M., Mukherjee N., Bermudez R.S., Latham D.E., Delaney M.A., Zietman A.L., Latham D.E., Delaney M.A., Zietman A.L., Shipley W.U., and Chakravarti A. Adenovirus-mediated inhibition of survivin expression sensitizes prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 64 (2005) 293-302
100. Wang Z., Sampath J., Fukuda S., and Pelus L.M. Disruption of the inhibitor of apoptosis protein survivin sensitizes bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 65 (2005) 8224-8232
101. Span P.N., Tjan-Heijnen V.C., Manders P., van Tienoven C., Lehr J., and Sweep F.C. High survivin predicts a poor response to endocrine therapy but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res. Treat. 98 (2006) 223-230
102. Rodel C., Haas J., Groth A., Grabenbauer G.G., Sauer R., and Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int. J. Rad. Oncol. Biol. Phys. 55 (2003) 1341-1347
103. Asanuma K., Moriai R., Yagihashi T.Yajima.A., Yamada M., Kobayashi D., and Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res. 91 (2000) 120-1204
104. Pennati M., Binda M., Colella G., Folini M., Citti L., Villa R., Daidone M.G., and Zaffaroni N. Radiosensitzation of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J. Invest. Dermatol. 120 (2003) 648-654
105. Chakravarti A., Zhai G.G., Zhang M., Malhotra R., Latham D.E., Delaney M.A., Robe P., Nestler U., Song Q., and Loeffler J. Survivin enhances radiation resistance in primary glioblastoma cells via caspase-independent mechanisms. Oncogene 23 (2004) 7494-7506
106. Kanwar J.R., Shen W.P., Kanwar R.K., Berg R.W., and Krissansen G.W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. 93 (2001) 1541-1552